Based on the above reports and our study, it is reasonable to believe that PLCG2 may stimulate rapid proliferation and metastasis of tumor cells by remodeling tumor microenvironment or activating specific signaling pathways, which contributes to poor efficacy of EGFR TKI treatment. The gene discussed is EGFR; the disease is neoplasm.